Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.68 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.68 |
| ▸ | FAAH | O00519 | 2/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19693898 | 1.00 | FFAR1 (0.68) | FFAR1FFAR4FAAHGPR84 | |
| SCHEMBL8482539 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 | |
| SCHEMBL350632 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 | |
| SCHEMBL9245664 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 | |
| SCHEMBL2431190 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 | |
| SCHEMBL6252089 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 | |
| SCHEMBL3904689 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 | |
| SCHEMBL18663452 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 | |
| SCHEMBL10533061 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 | |
| SCHEMBL6252064 | 0.93 | GPR84 (0.55) | FFAR1FFAR4GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174216-B2 | Lipids that increase insulin sensitivity and methods of using the same | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-2844303-B1 | LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-2972399-B1 | LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10604473-B2 | Lipids that increase insulin sensitivity and methods of using the same | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180194714-A1 | Lipids That Increase Insulin Sensitivity And Methods Of Using The Same | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2018-07-12 | — | — | US | disclosed |
| WO-2017214527-A1 | FATTY ACID ESTERS OF HYDROXY FATTY ACIDS (FAHFAS) FOR USE IN THE TREATMENT OF TYPE 1 DIABETES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20160221925-A1 | Lipids That Increase Insulin Sensitivity And Methods Of Using The Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-04 | — | — | US | disclosed |
| EP-2972399-A2 | LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME | Beth Israel Deaconess Medical Center, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150133551-A1 | Lipids That Increase Insulin Sensitivity And Methods Of Using The Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
| EP-2844303-A1 | LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME | Beth Israel Deaconess Medical Center, Inc. (US) | 2015-03-11 | — | — | EP | disclosed |
| WO-2014144777-A2 | LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013166431-A1 | LIPIDS THAT INCREASE INSULIN SENSITIVITY AND METHODS OF USING THE SAME | BETH ISREAL DEACONESS MEDICAL CENTER, INC. (US) | 2013-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221925-A1 | Lipids That Increase Insulin Sensitivity And Methods Of Using The Same | ELOVL1, ELOVL3, FADS1 | FFAR1 70/4885FFAR4 62/4885FAAH 206/4885 |
| US-20150133551-A1 | Lipids That Increase Insulin Sensitivity And Methods Of Using The Same | ELOVL1, FASN, ELOVL5 | FFAR1 79/4885FFAR4 93/4885FAAH 260/4885 |
| US-20180194714-A1 | Lipids That Increase Insulin Sensitivity And Methods Of Using The Same | ELOVL1, FASN, ELOVL5 | FFAR1 77/4885FFAR4 94/4885FAAH 263/4885 |
| US-10604473-B2 | Lipids that increase insulin sensitivity and methods of using the same | ELOVL1, ELOVL3, FADS1 | FFAR1 70/4885FFAR4 62/4885FAAH 206/4885 |
| US-11174216-B2 | Lipids that increase insulin sensitivity and methods of using the same | ELOVL1, FASN, ELOVL5 | FFAR1 77/4885FFAR4 94/4885FAAH 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.